Ulf Kulik1, Frank Lehner1, Jürgen Klempnauer1, Jürgen Borlak2. 1. Department of General-, Visceral- and Transplantation Surgery, Hannover, Germany. 2. Centre for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany.
Abstract
BACKGROUND & AIMS: The shortage of liver donations demands the use of suboptimal grafts with steatosis being a frequent finding. Although ≤30% macrovesicular steatosis is considered to be safe the risk for primary non-function (PNF) and outcome after re-transplantation (re-OLT) is unknown. METHODS: Among 1205 orthotopic liver transplantations performed at our institution the frequency, survival and reason of re-OLT were evaluated. PNF (group A) cases and those with initial transplant function but subsequent need for re-OLT (group B) were analysed. Histopathology and clinical judgement determined the cause of PNF and included an assessment of hepatic steatosis. Additionally, survival of fatty liver allografts (group C) not requiring re-OLT was considered in Kaplan-Meier and multivariate regression analysis. RESULTS: A total of 77 high urgency re-OLTs were identified and included 39 PNF cases. Nearly 70% of PNF cases were due to primary fatty liver allografts. The 3-month in-hospital mortality for PNF cases after re-OLT was 46% and the mean survival after re-OLT was 0.5 years as compared to 5.2 and 5.1 years for group B, C, respectively, (P<.008). In multivariate Cox regression analysis only hepatic steatosis was associated with an inferior survival (HR 4.272, P=.002). The MELD score, donor BMI, age, cold ischaemic time, ICU stay, serum sodium and transaminases did not influence overall survival. CONCLUSIONS: Our study highlights fatty liver allografts to be a major cause for PNF with excessive mortality after re-transplantation. The findings demand the development of new methods to predict risk for PNF of fatty liver allografts.
BACKGROUND & AIMS: The shortage of liver donations demands the use of suboptimal grafts with steatosis being a frequent finding. Although ≤30% macrovesicular steatosis is considered to be safe the risk for primary non-function (PNF) and outcome after re-transplantation (re-OLT) is unknown. METHODS: Among 1205 orthotopic liver transplantations performed at our institution the frequency, survival and reason of re-OLT were evaluated. PNF (group A) cases and those with initial transplant function but subsequent need for re-OLT (group B) were analysed. Histopathology and clinical judgement determined the cause of PNF and included an assessment of hepatic steatosis. Additionally, survival of fatty liver allografts (group C) not requiring re-OLT was considered in Kaplan-Meier and multivariate regression analysis. RESULTS: A total of 77 high urgency re-OLTs were identified and included 39 PNF cases. Nearly 70% of PNF cases were due to primary fatty liver allografts. The 3-month in-hospital mortality for PNF cases after re-OLT was 46% and the mean survival after re-OLT was 0.5 years as compared to 5.2 and 5.1 years for group B, C, respectively, (P<.008). In multivariate Cox regression analysis only hepatic steatosis was associated with an inferior survival (HR 4.272, P=.002). The MELD score, donor BMI, age, cold ischaemic time, ICU stay, serum sodium and transaminases did not influence overall survival. CONCLUSIONS: Our study highlights fatty liver allografts to be a major cause for PNF with excessive mortality after re-transplantation. The findings demand the development of new methods to predict risk for PNF of fatty liver allografts.
Authors: Hunter B Moore; Hillary Yaffe; James J Pomposelli; Michael Wachs; Thomas Bak; Peter Kennealey; Kendra Conzen; Megan Adams; Thomas Pshak; Rashikh Choudhury; Carson Walker; Alexander Schulick; Tanner Ferrell; Michael P Chapman; Elizabeth A Pomfret; Trevor L Nydam Journal: Am J Surg Date: 2020-08-27 Impact factor: 2.565
Authors: S Moosburner; P V Ritschl; L Wiering; J M G V Gassner; R Öllinger; J Pratschke; I M Sauer; N Raschzok Journal: Chirurg Date: 2019-09 Impact factor: 0.955
Authors: Jurgis Alvikas; Andrew-Paul Deeb; Dana R Jorgensen; Marta I Minervini; Anthony J Demetris; Kristina Lemon; Xilin Chen; Hanna Labiner; Shahid Malik; Christopher Hughes; Abhinav Humar; Amit Tevar Journal: Transplant Proc Date: 2021-04-27 Impact factor: 1.014
Authors: Ivana Mikolasevic; Tajana Filipec-Kanizaj; Maja Mijic; Ivan Jakopcic; Sandra Milic; Irena Hrstic; Nikola Sobocan; Davor Stimac; Patrizia Burra Journal: World J Gastroenterol Date: 2018-04-14 Impact factor: 5.742
Authors: Simon Moosburner; Joseph M G V Gassner; Maximilian Nösser; Julian Pohl; David Wyrwal; Felix Claussen; Paul V Ritschl; Duska Dragun; Johann Pratschke; Igor M Sauer; Nathanael Raschzok Journal: HPB Surg Date: 2018-11-01